Common stock
- Symbol
- DARE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Dare Bioscience, Inc.
DARENASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item Results 2.02 of Operations and Financial Condition. On August 13, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026, a copy of which is furnished as Exhibit 99.1 to this report.…
Company context
We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.
Current securities
Registered securities in this filing
DARE BIOSCIENCE, INC. · 8-K · Filed 2026-08-13
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item Results
2.02 of Operations and Financial Condition.
On
August 13, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the
quarter ended June 30, 2026, a copy of which is furnished as Exhibit 99.1 to this report.
The
information in this Item 2.02 and in Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation
by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions and preorders already being accepted Building a commercial ecosystem to make it easier for women to discover, access and purchase products specifically designed for women Clinical pipeline continues to advance, led by positive interim Phase 3 Ovaprene® results and initiation of the DARE-HPV Phase 2 study Company to host conference call and webcast today, August 13, 2026, at 4:30 p.m. Eastern Time - Access the webcast here SAN DIEGO, August 13, 2026 (GLOBE NEWSWIRE) - Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the quarter ended June 30, 2026, and provided a corporate …
Open exhibit ↗